Scientific Program

İstanbul MS Days

 

17:30 – 19:00 PANEL – In Turkish
Treatment options and barriers in treating the individual with MS in Turkiye
19:00 – 19:15 Rational Drug Use
  Dinner
09:00 – 09:45 Morning Satellite
10:00 - 10:45 Lecturing skills for young scientists
Janet Hafler
11:00 – 12:30 TURKISH MS PANEL – In Turkish with lunch
Building future-proof careers for young MS specialists in Türkiye
13:00 – 14:00 OFFICIAL OPENING
13:00 – 13:10 Welcome address 1: History of Istanbul MS Days
Aksel Siva
13:10 – 13:20 Welcome address 2: From local roots to global aspirations – Dark Side of the Moon?
Orhun H. Kantarci
13:20 – 17:20 SESSION-1 / I: From Posers’ Criteria to refined disease definitions of 2024 in inflammatory demyelinating diseases
Discussants & Chairs: Jack Antel & Husnu Efendi & Axel Petzold
13:20 – 13:40 The clinician-scientist – finding the right questions for the right answers
Brian G. Weinshenker
13:40 – 14:00 The scientist-clinician – using epidemiology evidence to develop individualized clinical practice
Ellen Mowry
14:00 – 14:20 The clinician-clinician – Value of experience-based medicine in the extremes of disease
Thomas Berger
14:20 – 14:40 The scientist-scientist – Developing models that reflect clinical questions accurately
Katerina Akkasoglu
14:40 – 15:00 Discussion
15:00 – 15:20 Break
15:20 – 17:30 SESSION-1 / II: Updates in Diagnostic Criteria and phenotyping definitions of inflammatory demyelinating diseases in 2024 and beyond
Discussants & Chairs: Jack Antel & Husnu Efendi & Axel Petzold
15:20 – 15:40 The 2024 MS Diagnostic Criteria – What does it change?
Xavier Montalban
15:40 – 16:00 Upcoming IPND-2025 Criteria – Will it add anything?
Kazuo Fujihara
16:20 – 17:00 Do we need more detailed or more practical diagnostic criteria?
TBA
17:00 – 17:30 Q&A, Discussion
17:30 – 17:50 Break
17:50 – 20:00 SESSION-2: Can we use science to fine tune health care delivery to the underserved?
Discussants & Chairs: Mohamadali Sahraian & Magd Zakaria & TBA
17:50 – 18:10 The real-world needs of the underserved countries
Riad Goudhier
18:10 – 18:30 Pitfalls in quantifying needs of the underserved and how to improve it
TBA
18:30 – 18:50 Socialized vs. free-market economy for delivering healthcare to people in need
TBA
18:50 – 19:00 Objective definitions of race & ethnicity – beyond the conventional
Philip L. De Jager
19:00 – 19:20 Adjusting for geography in epidemiology studies in MS
Alberto Ascherio
19:20 – 19:50 Q&A, Discussion
20:20 Dinner
08:00 - 09:00 Oral abstract presentations
09:00 – 09:20 Break
09:20 – 12:00 SESSION-3: Translating existing biomarkers to clinic?
Discussants & Chairs: Naila Makhani & Turkish Co-Chair
09:20 - 09:40 Low field portable MRI - effective deployment to clinic –
Serhat Okar
09:40 - 10:00 Real world use examples of CVS & PRLs
Jiwon Oh
10:00 - 10:20 Utility of cervical cord MRI in MS diagnosis and prognosis
Cristina Azevedo
10:20 – 10:40 Break
10:40 – 11:00 CSF biomarkers in MS
Hayrettin Tumani
11:00 – 11:20 Integrating multiple biomarkers to diagnose, prognosticate and treat in the real world – The RIS experience
Darin Okuda
11:20 – 12:00 Q&A, Discussion
12:00 – 13:00 Lunch Satellite
13:00 – 15:20 SESSION-4: Translating “futureomics” to clinic today?
Chairs / Panelists: Boris Zalc & Turkish Co-Chair TBA
13:00 – 13:20 Role of genomics in early diagnosis of MS
Anat Achiron
13:20 - 13:40 Power of bioinformatics to solve complex proteomics of MS -
Mika Gustaffson
13:40 – 14:00 Immunomics to practice in MS
Amit Bar-Or
14:00 – 14:20 Break
14:20 – 14:40 Radiomics to delineate complex phenotypes in MS
Korhan Büyüktürkoğlu
14:40 - 15:00 Pitfalls of integrating omics – human vs AI?
Vilas Menon
15:00 – 15:20 Q & A Discussion
15:20 - 15:40 Break
15:40 – 18:00 SESSION-5: The MS continuum - polymorphic definition of relapses and progressive MS
Discussants & Chairs: TBA & Turkish Co-Chair
15:40 – 16:00 The pathologist’s view of MS phenotypes
Bruce Trapp
16:00 – 16:20 MRI markers of MS phenotypes
Daniel Ontaneda
16:20 - 16:40 Non-MRI imaging biomarkers of MS phenotypes
Peter A. Calabresi
16:40 – 17:00 Break
17:00 – 17:20 Relapses & Pseudorelpases – do we need updated definitions
Eoin P. Flanagan
17:20 - 17:40 Towards practical composite metrics of preclinical and subclinical MS definitions
Orhun Kantarcı
17:40 – 18:00 Q&A, Discussion
18:00 - 18:20 Break
18:20 – 19:50 SESSION-6: Using molecular imaging in MS – towards a practical goal
Discussants & Chairs: Najib Kissani & Turkish Co-Chair & Catherine Lubetzki
18:20 - 18:40 PET markers of myelin and oligodendrocytes
Burcu Zeydan
18:40 – 19:00 PET markers of microglia function
Laura Airas
19:00 – 19:20 PET Astrocyte imaging markers
TBA
19:20 - 19:50 Q&A, Discussion
20:15 Dinner
08:00 - 09:00 Oral presentations
09:00 – 09:15 Break
09:15 – 12:00 SESSION-7: The treatment of MS today and tomorrow
Chairs / Panelists: Rana Karabudak & Dimitrios Karussis & Samia Khoury
09:15 - 09:35 Treating MS in the young age
Silvia Tenembaum
09:35 – 09:55 How to treat MS in the old age
Nikolaos Grigoriadis
09:55 - 10:15 Hormones and adjunct therapies in MS
TBA
10:15 - 10:30 Break
10:30 – 10:50 New developments in B cell depletion
David Hafler
10:50 – 11:10 Microglia targets – BTK inhibitors and beyond  
Daniel Reich
11:10– 11:30 How to apply advanced imaging modalities for future clinical trials
Nicola De Stefano
11:30 – 12:00 Q&A, Discussion
12:00 – 13:00 Lunch Satellite
13:00 – 15:30 SESSION-8: Rethinking trial design in multiple sclerosis
Chairs / Panelists: Hans-Peter Hartung & Turkish Co-Chair & Turkish Co-Chair
13:00 – 13:20 Sex and ethnicity impact on clinical trial results
TBA
13:20 - 13:40 Impact of limited recovery from relapses in practice and in clinical trials
Claire Riley
13:40 – 14:00 Designing future proof clinical trials with multiple variables a priori
Maria Pia Sormani
14:00 – 14:20 Break
14:20 – 14:40 Missing spinal cord data and beyond in clinical trials – mismatch with clinical practice
Matilde Inglese
14:40 - 15:00 Using AI to model for prognostic variables in clinical trials
Cristina Granziera
15:00 – 15:30 Q & A, Discussion
15:30 - 15:45 Break
15:45 – 18:30 SESSION-9: Treating the whole spectrum
Discusssants & Chairs:  Jacqueline Palace & Paulus Rommer & Turkish Co-Chair
15:45 – 16:05 Sensitivity and specificity of laboratory biomarkers in MS, NMO and MOG
Orhan Aktas
16:05 – 16:25 The challenges of treating overlapping autoimmune diseases with MS
Aksel Siva
16:25 – 16:45 The new NMO era of treating NMO – What should be the first line?
Friedemann Paul
16:45 – 17:05 Treating MOGAD – where are we now?
TBA
17:05 – 17:20 Break
17:20 – 17:40 mRNA vaccines for MS and autoimmune diseases
TBA
17:40 – 18:00 Where is the next innovation in treating inflammatory-demyelinating disease spectrum
Heinz Wiendl
18:00 – 18:30 Q&A, Discussion
18:30 - 18:45 Break
18:45 – 19.15 Istanbul MS Days Lecture
Chairs: Rana Karabudak & Husnu Efendi & Orhun Kantarcı & Aksel Siva
  Potential for overcoming regulatory limitations on off-label use of immunomodulation through large consensus statements
Giancarlo Comi
19:15 – 20:15 Summary and review of the meeting by the young Turkish MS Experts
20:30 Faculty - Farewell Dinner